Interferon alpha-2b - Beijing Kawin Technology

Drug Profile

Interferon alpha-2b - Beijing Kawin Technology

Alternative Names: Interferon alpha-2b vaginal effervescent tablet - Beijing Kawin technology; Recombinant human interferon alpha-2b injection - Beijing Kawin technology

Latest Information Update: 28 Aug 2015

Price : $50

At a glance

  • Originator Beijing Kawin Technology Share-Holding
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Basal cell cancer; Chronic myeloid leukaemia; Condylomata acuminata; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Herpes zoster; Kaposi's sarcoma; Lymphoma; Malignant melanoma; Multiple myeloma; Ovarian cancer; Renal cancer; Uterine diseases

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Aug 2015 Launched for Basal cell cancer in China (Intratumoural) before August 2015
  • 27 Aug 2015 Launched for Chronic myeloid leukaemia in China (IM) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top